| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Serine/threonine-protein kinase 4 |
|---|
| Ligand | BDBM50024294 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_325027 (CHEMBL860661) |
|---|
| Kd | 2200±n/a nM |
|---|
| Citation |  Fabian, MA; Biggs, WH; Treiber, DK; Atteridge, CE; Azimioara, MD; Benedetti, MG; Carter, TA; Ciceri, P; Edeen, PT; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Mehta, SA; Milanov, ZV; Velasco, AM; Wodicka, LM; Patel, HK; Zarrinkar, PP; Lockhart, DJ A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol23:329-36 (2005) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Serine/threonine-protein kinase 4 |
|---|
| Name: | Serine/threonine-protein kinase 4 |
|---|
| Synonyms: | KRS2 | MST1 | STK4 | STK4_HUMAN | Serine/threonine-protein kinase 3/4 | Serine/threonine-protein kinase 4 (STK4) | Serine/threonine-protein kinase MST1 |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 55611.40 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q13043 |
|---|
| Residue: | 487 |
|---|
| Sequence: | METVQLRNPPRRQLKKLDEDSLTKQPEEVFDVLEKLGEGSYGSVYKAIHKETGQIVAIKQ
VPVESDLQEIIKEISIMQQCDSPHVVKYYGSYFKNTDLWIVMEYCGAGSVSDIIRLRNKT
LTEDEIATILQSTLKGLEYLHFMRKIHRDIKAGNILLNTEGHAKLADFGVAGQLTDTMAK
RNTVIGTPFWMAPEVIQEIGYNCVADIWSLGITAIEMAEGKPPYADIHPMRAIFMIPTNP
PPTFRKPELWSDNFTDFVKQCLVKSPEQRATATQLLQHPFVRSAKGVSILRDLINEAMDV
KLKRQESQQREVDQDDEENSEEDEMDSGTMVRAVGDEMGTVRVASTMTDGANTMIEHDDT
LPSQLGTMVINAEDEEEEGTMKRRDETMQPAKPSFLEYFEQKEKENQINSFGKSVPGPLK
NSSDWKIPQDGDYEFLKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQSKRQPILDAIEAK
KRRQQNF
|
|
|
|---|
| BDBM50024294 |
|---|
| n/a |
|---|
| Name | BDBM50024294 |
|---|
| Synonyms: | SP-600125 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C14H8N2O |
|---|
| Mol. Mass. | 220.2261 |
|---|
| SMILES | Oc1c2cccc3N=Nc(c23)c2ccccc12 |c:7| |
|---|
| Structure | 
|
|---|
Search and Browse
